Indivior Pharmaceuticals Reports 19% Revenue Growth to $317 Million in Q1 2026

Indivior Pharmaceuticals, Inc. reported a significant increase in financial performance for the first quarter of 2026, with net revenue reaching $317 million, a 19% increase from $266 million in the same period of 2025. The company's gross profit also rose to $277 million, compared to $221 million a year earlier, resulting in a gross margin of 87%, up from 83%. Net income for the quarter was $89 million, or $0.71 per share, compared to $47 million, or $0.38 per share, in the prior year. This growth was primarily driven by a 33% increase in U.S. sales of SUBLOCADE, which accounted for 73% of total revenue.

The company experienced notable changes in its operating expenses, which decreased by 10% to $139 million from $156 million in the previous year. Selling, general, and administrative expenses fell by 7% to $124 million, attributed to headcount reductions and cost-saving measures under the Indivior Action Agenda. Research and development expenses also decreased by 28% to $16 million, reflecting a reprioritization of pipeline activities. The company incurred an $18 million loss on debt extinguishment due to the repayment of its previous term loan, which was offset by a reduction in net interest expense.

Strategically, Indivior completed a redomiciliation to the United States in January 2026, which included a corporate restructuring that did not impact historical financials. The company also launched a $400 million share repurchase program, repurchasing approximately 4 million shares for $125 million during the quarter. Additionally, Indivior successfully issued $500 million in convertible senior notes due in 2031, with proceeds used to repay existing debt and support ongoing operations.

Operationally, Indivior's customer engagement metrics showed positive trends, with SUBLOCADE dispense unit volume growth of 20% in the U.S. The company reported a decrease in accrued rebates and product returns to $555 million, down from $678 million a year earlier, indicating improved cash flow management. The total number of shares outstanding as of April 1, 2026, was 121,922,058, reflecting the impact of the share repurchase program.

Looking ahead, Indivior aims to accelerate growth through its Action Agenda, focusing on increasing SUBLOCADE dispense unit growth and net revenue. The company anticipates continued investment in its manufacturing capabilities, particularly with the construction of a new facility in Raleigh, North Carolina. Indivior's management remains optimistic about maintaining liquidity and meeting its financial obligations, despite the challenges posed by ongoing litigation and market conditions.